Three cases of severe hepatic impairment caused by erlotinib

被引：15

作者：

Huang, Yi-Sheng ^{[1
]}

An, She-Juan ^{[1
]}

Chen, Zhi-Hong ^{[1
]}

Wu, Yi-Long ^{[1
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 68卷 / 03期

关键词：

CELL LUNG-CANCER; PHASE-III; TARCEVA; TRIAL;

D O I：

10.1111/j.1365-2125.2009.03459.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：464 / 467

页数：4

共 13 条

[1] Preclinical studies with erlotinib (Tarceva) [J].

Akita, RW ;

Sliwkowski, MX .

SEMINARS IN ONCOLOGY, 2003, 30 (03) :15-24

[2] CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .1. A NOVEL METHOD BASED ON THE CONCLUSIONS OF INTERNATIONAL CONSENSUS MEETINGS - APPLICATION TO DRUG-INDUCED LIVER INJURIES [J].

DANAN, G ;

BENICHOU, C .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1323-1330

[3] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].

Gatzemeier, Ulrich ;

Pluzanska, Anna ;

Szczesna, Aleksandra ;

Kaukel, Eckhard ;

Roubec, Jaromir ;

De Rosa, Flavio ;

Milanowski, Janusz ;

Karnicka-Mlodkowski, Hanna ;

Pesek, Milos ;

Serwatowski, Piotr ;

Ramlau, Rodryg ;

Janaskova, Terezie ;

Vansteenkiste, Johan ;

Strausz, Janos ;

Manikhas, Georgy Moiseevich ;

Von Pawel, Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552

[4] Erlotinib in non-small cell lung cancer treatment: Current status and future development [J].

Gridelli, Cesare ;

Bareschino, Maria Anna ;

Schettino, Clorinda ;

Rossi, Antonio ;

Maione, Paolo ;

Ciardiello, Fortunato .

ONCOLOGIST, 2007, 12 (07) :840-849

[5] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[6]

Hsieh KP, 2001, DRUG METAB DISPOS, V29, P268

[7] PHARMACOGENETICS IN CLINICAL-PHARMACOLOGY AND TOXICOLOGY [J].

INABA, T ;

NEBERT, DW ;

BURCHELL, B ;

WATKINS, PB ;

GOLDSTEIN, JA ;

BERTILSSON, L ;

TUCKER, GT .

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (03) :331-338

[8] SIGNIFICANCE OF CYTOCHROME-P-450 (P-450-HFLA) OF HUMAN-FETAL LIVERS IN THE STEROID AND DRUG OXIDATIONS [J].

KITADA, M ;

KAMATAKI, T ;

ITAHASHI, K ;

RIKIHISA, T ;

KANAKUBO, Y .

BIOCHEMICAL PHARMACOLOGY, 1987, 36 (04) :453-456

[9]

LING JI, 2002, CHINESE MED J, V115, P1780

[10] Fulminant hepatic failure secondary to erlotinib [J].

Liu, Weitian ;

Makrauer, Frederick L. ;

Qamar, Amir A. ;

Jaenne, Pasi A. ;

Odze, Robert D. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (08) :917-920

← 1 2 →